ImmunityBio, Inc. (IBRX)
Market: NASD |
Currency: USD
Address: 3530 John Hopkins Court
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Show more
📈 ImmunityBio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$11.40
-
Upside/Downside from Analyst Target:
301.41%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
>500%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for ImmunityBio, Inc.
| Date | Reported EPS |
|---|
| 2026-05-11 (estimated upcoming) | - |
| 2026-03-02 (estimated upcoming) | - |
| 2025-11-10 (estimated upcoming) | - |
| 2025-11-09 (estimated upcoming) | - |
| 2025-08-11 (estimated upcoming) | - |
| 2025-08-10 (estimated upcoming) | - |
| 2025-05-12 | -0.15 |
| 2025-05-08 | - |
| 2025-05-07 | - |
| 2025-05-06 | - |
| 2025-03-16 | - |
| 2025-03-03 | -0.09 |
| 2024-11-12 | -0.12 |
| 2024-08-12 | -0.2 |
| 2024-08-11 | -0.2 |
| 2024-05-09 | -0.2 |
| 2024-05-08 | -0.2 |
| 2024-03-19 | -0.35 |
| 2024-03-18 | -0.35 |
| 2023-11-09 | -0.19 |
| 2023-11-08 | -0.19 |
| 2023-08-08 | -0.32 |
| 2023-08-07 | -0.32 |
| 2023-05-11 | -0.27 |
| 2023-05-10 | -0.27 |
| 2023-03-01 | -0.27 |
| 2023-02-28 | -0.27 |
| 2022-11-09 | -0.28 |
| 2022-11-08 | -0.28 |
| 2022-08-08 | -0.24 |
| 2022-08-07 | -0.24 |
| 2022-05-10 | -0.26 |
| 2022-05-09 | -0.26 |
| 2022-03-01 | -0.23 |
| 2022-03-01 | -0.23 |
| 2021-11-12 | -0.22 |
| 2021-11-11 | -0.22 |
| 2021-08-12 | -0.23 |
| 2021-08-11 | -0.23 |
| 2021-05-14 | -0.21 |
| 2021-05-13 | -0.21 |
| 2021-03-04 | -0.3 |
| 2021-03-03 | -0.3 |
| 2020-11-09 | -0.2 |
| 2020-11-08 | -0.2 |
| 2020-08-07 | -0.2 |
| 2020-08-06 | -0.2 |
| 2020-05-11 | -0.19 |
| 2020-05-10 | -0.19 |
| 2020-03-25 | -0.16 |
| 2020-03-24 | -0.16 |
| 2019-11-04 | -0.16 |
| 2019-08-05 | -0.17 |
| 2019-05-07 | -0.22 |
| 2019-03-12 | -0.22 |
| 2018-11-06 | -0.3 |
| 2018-08-05 | -0.35 |
| 2018-05-06 | -0.35 |
| 2018-03-11 | -0.31 |
| 2017-11-06 | -0.3 |
| 2017-08-06 | -0.29 |
| 2017-05-07 | -0.3 |
| 2017-03-14 | -0.29 |
| 2016-11-09 | -0.39 |
| 2016-08-14 | -0.41 |
| 2016-05-15 | -0.38 |
| 2016-03-29 | -0.97 |
| 2015-11-11 | -0.55 |
| 2015-09-09 | -1.29 |
| 2015-07-30 | - |
📰 Related News & Research
No related articles found for "immunitybio inc".
